Edmond DE Rothschild Holding S.A. Takes $254,000 Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Edmond DE Rothschild Holding S.A. bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 10,500 shares of the company’s stock, valued at approximately $254,000.

Several other institutional investors have also bought and sold shares of the stock. Charles Schwab Investment Management Inc. lifted its holdings in shares of Hims & Hers Health by 15.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company’s stock valued at $30,714,000 after acquiring an additional 218,566 shares during the period. Rockefeller Capital Management L.P. lifted its holdings in Hims & Hers Health by 5.8% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 33,775 shares of the company’s stock valued at $622,000 after purchasing an additional 1,864 shares during the last quarter. Centiva Capital LP lifted its holdings in Hims & Hers Health by 13.1% during the 3rd quarter. Centiva Capital LP now owns 81,811 shares of the company’s stock valued at $1,507,000 after purchasing an additional 9,468 shares during the last quarter. HighTower Advisors LLC acquired a new position in Hims & Hers Health in the third quarter valued at about $207,000. Finally, Quarry LP grew its stake in Hims & Hers Health by 91.0% during the third quarter. Quarry LP now owns 6,113 shares of the company’s stock worth $113,000 after buying an additional 2,913 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on HIMS. Piper Sandler boosted their target price on Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a report on Tuesday, February 25th. Citigroup reiterated a “sell” rating and issued a $27.00 price objective on shares of Hims & Hers Health in a research report on Thursday, March 6th. Canaccord Genuity Group increased their target price on Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, February 19th. Bank of America lifted their price target on Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a report on Tuesday, March 18th. Finally, BTIG Research began coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $37.31.

Hims & Hers Health Stock Performance

Hims & Hers Health stock opened at $31.16 on Thursday. Hims & Hers Health, Inc. has a 52 week low of $11.20 and a 52 week high of $72.98. The stock has a market capitalization of $6.92 billion, a P/E ratio of 70.82 and a beta of 1.37. The stock has a fifty day moving average of $39.97 and a 200-day moving average of $29.79.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. On average, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Transactions at Hims & Hers Health

In related news, CEO Andrew Dudum sold 36,460 shares of the firm’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $27.09, for a total transaction of $987,701.40. Following the completion of the transaction, the chief executive officer now directly owns 27,918 shares of the company’s stock, valued at $756,298.62. This trade represents a 56.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Soleil Boughton sold 268,932 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $27.75, for a total value of $7,462,863.00. Following the transaction, the insider now owns 169,803 shares of the company’s stock, valued at $4,712,033.25. This trade represents a 61.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,064,954 shares of company stock worth $37,984,259. Corporate insiders own 17.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.